1849590-01-7 Usage
Description
eFT508 is a potent inhibitor of MAPK interacting protein kinases (MNK) 1 and 2 (IC50s = <10 nM). It inhibits phosphorylation of eukaryotic initiation factor 4E (eIF4E) with an IC50 value of <50 nM in a cellular signaling assay. eFT508 has a half-life of 5.3 hours in rats.
Uses
6''-[(6-Amino-4-pyrimidinyl)amino]-8''-methylspiro[cyclohexane-1,3''(2''H)-imidazo[1,5-a]pyridine]-1'',5''-dione was used in the study of inhibitors of immune checkpoint modulators and related methods. eFT508 is a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor.
Check Digit Verification of cas no
The CAS Registry Mumber 1849590-01-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,4,9,5,9 and 0 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1849590-01:
(9*1)+(8*8)+(7*4)+(6*9)+(5*5)+(4*9)+(3*0)+(2*0)+(1*1)=217
217 % 10 = 7
So 1849590-01-7 is a valid CAS Registry Number.
1849590-01-7Relevant articles and documents
CRYSTALLINE FORMS OF MNK INHIBITORS
-
Paragraph 0095; 0099-0100, (2020/05/14)
The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
